The U.K. drugmaker will wait for results of a trial on the drug’s effectiveness in combination with chemotherapy compared with chemotherapy alone before deciding whether to submit Recentin to regulators for approval, it said in an e-mailed statement today. AstraZeneca said the setback doesn’t affect its financial forecast for this year or for the period 2010 to 2014.
AstraZeneca was trying to prove its drug candidate wasn’t inferior to Avastin in keeping patients alive without their disease progressing. The company’s still collecting data on overall survival.
“While we recognized that challenging Avastin would be a high hurdle, it is still disappointing,” said Alan Barge, head of oncology at AstraZeneca, in the statement.